Aflatoxin and liver cancer
Aflatoxin and liver cancer
复制标题
DOI：
10.1053/bega.1999.0047
复制
发表时间：
1999-12-01
影响因子：
3.2
通讯作者：
Groopman, JD
中科院分区：
文献类型：
--
作者：
Jackson, PE;Groopman, JD
本章回顾了已经积累的数据，涉及黄曲霉毒素摄入作为肝细胞癌（HCC）的病因学的一个重要的危险因素。许多流行病学研究已经观察到高黄曲霉毒素暴露地区与HCC高发病率之间的相关性。黄曲霉毒素暴露的实验模型和特定生物标志物的使用，如尿代谢产物或黄曲霉毒素加合物，已经验证了这些发现。正在中国启东进行的临床试验表明，奥替普拉（一种化学预防剂）可通过减少黄曲霉毒素代谢为致癌形式并增加这些代谢物的解毒途径，降低黄曲霉毒素的生物有效剂量。使用这类化学品进行干预，同时实施B型肝炎病毒免疫方案和改善主食的储存条件，是可以采取的预防措施，以减少高风险地区的肝癌发病率。
This chapter reviews the data that have been accumulated implicating aflatoxin ingestion as an important risk factor in the aetiology of hepatocellular carcinoma (HCC). Numerous epidemiological studies have observed a correlation between areas of high aflatoxin exposure and a high incidence of HCC. The use of experimental models and specific biomarkers for aflatoxin exposure, such as urinary metabolites or aflatoxin adducts, have validated these findings. Ongoing clinical trials in Qidong, China, have indicated that oltipraz, a chemopreventive agent, can lower the biologically effective dose of aflatoxins by decreasing the metabolism of aflatoxin to its carcinogenic form and increasing the detoxification pathways of these metabolites. Intervention with chemicals such as these, alongside hepatitis B virus immunization programmes and improved storage conditions of staple foods, are prevention measures that can be undertaken to reduce the incidence of HCC in high-risk regions.